Bepotastine besilate ophthalmic solution 1.5% clears the hurdle for allergic ocular itching
The FDA Dermatologic and Ophthalmic Drugs Advisory Committee has recommended the approval of bepotastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) for treating ocular itching associated with allergic conjunctivitis.
Key Points
Irvine, CA-The FDA Dermatologic and Ophthalmic Drugs Advisory Committee has recommended the approval of bepotastine besilate ophthalmic solution 1.5% (Bepreve, ISTA Pharmaceuticals) for treating ocular itching associated with allergic conjunctivitis.
The FDA still is required to approve the application and has set a date of Sept. 12 to take further action on the drug.
Bepotastine besilate is an eye-drop treatment that acts as a non-sedating, highly selective antagonist of the histamine receptor. It has been approved in Japan since 2000 to treat allergic rhinitis and urticaria/pruritus.
Newsletter
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.
